ExpertED@SSO: Premiere Education for Cancer Surgeons
Learn More About Current Controversies in Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer
Register now for the new webinar, “Current Controversies in Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer,” on November 26, 2018 at 5:30 pm EST. Despite expert consensus that patients with localized but not clearly resettable pancreatic ductal adenocarcinoma (PDAC) should receive some form of neoadjuvant therapy, this intervention is not uniformly practiced. This webinar will identify the benefits of neoadjuvant therapy in patients with PDAC, compare options for neoadjuvant therapy and have a better understanding of how to assess current practices. Faculty for this program include Clifford Cho, MD, Theodore S. Hong, MD, Christina R. Ferrone, MD and Robert A. Wolff, MD.